Unlocking fresh perspectives: molecular breakthroughs in pediatric acute myeloid leukemia classification and prognosis

Yu Tao; Li Wei; Hua You

doi:10.1002/mco2.750

MedComm ›› 2024, Vol. 5 ›› Issue (10) : e750 DOI: 10.1002/mco2.750

HIGHLIGHT

Unlocking fresh perspectives: molecular breakthroughs in pediatric acute myeloid leukemia classification and prognosis

Yu Tao ¹
, Li Wei ²
, Hua You ¹^,^†

Author information +

History +

PDF

Keywords

clinical outcomes / molecular categories / pediatric acute myeloid leukemia / risk stratification

Cite this article

Download citation ▾

Yu Tao, Li Wei, Hua You. Unlocking fresh perspectives: molecular breakthroughs in pediatric acute myeloid leukemia classification and prognosis. MedComm, 2024, 5(10): e750 DOI:10.1002/mco2.750

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Umeda M, Ma J, Westover T, et al. A new genomic framework to categorize pediatric acute myeloid leukemia. Nat Genet. 2024; 56(2): 281-293.

[2]	Mrózek K, Kohlschmidt J, Blachly JS, et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023; 37(4): 788-798.

[3]	Pollard JA, Alonzo TA, Gerbing R, et al. Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3/ITD+ acute myeloid leukemia: a report from the children’s oncology group protocol AAML1031. J Clin Oncol. 2022; 40(18): 2023-2035.

[4]	Rubnitz JE, Lacayo NJ, Inaba H, et al. Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: the AML08 multicenter, randomized phase III trial. J Clin Oncol. 2019; 37(23): 2072-2081.

[5]	Liu T, Rao J, Hu W, et al. Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification. Nat Commun. 2022; 13(1): 1640.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.